Allurion amends notes/RIFAs with cash & revenue covenants, FDA/France deadlines; reports AUDACITY trial topline results

ALLURION TECHNOLOGIES, INC.

Omnibus Amendment imposes minimum cash balances and minimum trailing 12-month revenue tested quarterly starting Q3 2025.
Deadlines: French marketing authorization by Dec 31, 2025; FDA US marketing authorization by June 30, 2026.
Amendment fee: 5% fully-diluted shares to investors after $12M+ offering by Feb 15, 2025; else Series A-1 preferred redeemable Dec 31, 2026.
RTW gets second board seat; Jason Richey appointed to board alongside Nicholas Lewin.
Announced topline results from AUDACITY trial of Allurion Balloon; details in press release Exhibit 99.4.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.